Dicliptera chinensis (L.) Juss. polysaccharide alleviates metabolic dysfunction-associated steatotic liver disease by regulating miR-3073b-5p/CAMKK2 via the gut microbiota-bile acid axis.
文献摘要
Dicliptera chinensis (L.) Juss. is a herbaceous plant renowned for its anti-inflammatory and antioxidant properties. Previous studies have demonstrated that its polysaccharide (DCP) exerts hepatoprotective effects, yet the underlying mechanism by which DCP alleviates metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. This study investigated the hepatoprotective effects of DCP in high-glucose and high-fat (HHF) diet-induced MASLD mice and AML12 hepatocytes, with a focus on miRNA-mediated regulatory mechanisms. Small RNA sequencing revealed that miR-3073b-5p was significantly upregulated in MASLD. Dual-luciferase reporter assays verified the direct binding of miR-3073b-5p to the 3'UTR of CAMKK2, and RIP assays further confirmed their interaction under physiological conditions. In vivo, DCP administration significantly ameliorated hyperglycemia, dyslipidemia, hepatic steatosis, and oxidative injury. 16S rRNA sequencing and bile acid metabolomics analyses demonstrated that DCP effectively reshaped the gut microbiota composition and restored bile acid metabolic homeostasis. In vitro, DCP downregulated miR-3073b-5p expression, thereby relieving the suppression of CAMKK2, regulating the AMPK/mTOR/Nrf2 signaling axis, restoring autophagy, and counteracting ferroptosis. These findings indicate that DCP alleviates MASLD by regulating miR-3073b-5p/CAMKK2 via the gut microbiota-bile acid axis, positioning it as a promising natural polysaccharide for MASLD therapy and providing a novel molecular target for the targeted intervention of this disease.